Full Year 2024 Telix Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Telix Pharmaceuticals Ltd (TLPPF) reported a 56% increase in revenue, surpassing guidance.
- The company achieved a 70% improvement in adjusted EBIT, reaching $99 million.
- Telix Pharmaceuticals Ltd (TLPPF) saw an 80% improvement in operating cash inflow.
- Profit after tax improved by 860%, showcasing strong financial performance.
- The company ended the year with a solid cash position of $710 million, bolstered by a convertible bond placement.
- The company faces uncertainties in the US healthcare system, which could impact future growth.
- Regulatory approval delays in the US could affect the launch of new products.
- The expiration of CMS pass-through status for Eustic could impact revenue in the second half of 2025.
- There is a risk of market cannibalization between new and existing products.
- The company has not yet included potential revenue from new product launches and territories in its guidance, indicating uncertainty in future financial projections.
Thank you, Ashley, and thank you everybody for joining us this morning Australian time. We're pleased to share with you our full year results for 2024, which we lodged with the ASX yesterday afternoon Australian time aftermarket closed. Just flicking through our standard disclaimer. I am joined today by Chris Benbrook, our managing director and group CEO, Darren Smith, our group CFO, Kevin Richardson, our CEO of the Telex Precision medicine business. And Richard Valle, the CEO of Telix Pharmaceuticals Ltd. Together we will be taking you through our performance, financial results and focus for 2025.
If we could move to slide 5, please.
Just by way of some introductory remarks, 2024 is going to be once again been an extraordinary year for Telex. We are delivering against all aspects of our growth strategy, and some of these operational highlights include the continued strong commercial performance driven by sales of aleix and the creation of a platform for further growth as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
